Latest Breaking News On - Holli kolkey - Page 3 : vimarsana.com

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Announces New Employment Inducement Grants
bdtonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bdtonline.com Daily Mail and Mail on Sunday newspapers.

United statesPia banerjeeHolli kolkeyCompany manual ruleCorporate communicationsCompany board of directorsArcus biosciences incCompensation committeeArcus bioscienceInvestor inquiriesInvestor relationsBusiness wire

Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Holli kolkeyCorporate communicationsAnnual evercoreArcus biosciencesArcus bioscienceInvestor relations

Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update

Data were presented from the ongoing EDGE-Gastric Phase 2 study in first-line upper GI cancers at the Annual Meeting of the American Society of Clinical Oncology (ASCO) Plenary Series; domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first-to-.

United statesHolli kolkeyTerry rosenArcus biosciences incCorporate communicationsCompany annual report on formExchange commission onExchange commissionDevelopment rd expensesGastric phaseAnnual meetingAmerican societyClinical oncologyPlenary seriesArcus biosciencesThird quarter

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-

– Preliminary data from Arm A1 of the Phase 2 EDGE-Gastric study showed promising ORR and six-month PFS results, irrespective of PD-L1 expression –– Domvanalimab is the only Fc-silent anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas and has the potential to be first to market for these cancers –– Detailed.

United statesFoster cityJacquie rossMeaghan smithHolli kolkeyYelenay janjigianGilead public affairsArcus biosciences incMemorial sloan kettering cancer centerAmerican society of clinical oncologyGilead sciencesPhysician of the gastrointestinal medical oncology serviceExchange commissionGilead sciences incPlenary seriesArcus biosciences

Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7

Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHolli kolkeyYelenay janjigianPia banerjeeAmerican society of clinical oncologyArcus biosciences incMemorial sloan kettering cancer centerMemorial sloan kettering cancer center onGilead sciencesCorporate communicationsPlenary seriesChief gastrointestinal oncologyAmerican societyClinical oncologyMonthly plenary seriesMonthly plenary session